Skip to main content
. 2020 Jul 24;10:1240. doi: 10.3389/fonc.2020.01240

Figure 2.

Figure 2

Saliva-based EFIRM for detection of exon19 del EGFR and p.E545K PIK3CA in Case 1. (A) The volume of metastatic tumor showed a sharp decline after the initiation with 80 mg osimertinib. At the time point of day 280 (black arrow), LAT and followed osimertinib re-initiation were performed. The tumor volume increased to a high level eventually. (B) The curve of exon19 del EGFR EFIRM has a strong similarity to that of exon19 del EGFR ddPCR (R = 0.53, P = 0.01). (C) The curve of p.E545K PIK3CA EFIRM has a strong similarity to that of p.E545K PIK3CA NGS (R = 0.72, P = 0.00), respectively.